TSX runs higher on rate cut expectations
HAYWARD, Calif. - Pulse Biosciences, Inc. (NASDAQ:PLSE), a $1.11 billion market cap medical technology company with strong liquidity metrics, announced that a first-in-human clinical feasibility study has demonstrated the effectiveness of its Nanosecond Pulsed Field Ablation (nsPFA) technology for treating benign thyroid nodules, according to a new publication in the Journal Thyroid. InvestingPro data shows the company maintains a healthy current ratio of 12.05, indicating robust operational flexibility.
The single-arm study, conducted at Ospedale del Mare in Naples, Italy, showed that fully treated nodules experienced up to 93% reduction in size at one year, with an average reduction of 86%. Patients reported symptom relief and nodule reduction of more than 48% as early as two weeks after treatment. With analysts setting a $22 price target and expecting profitability this year, according to InvestingPro analysis, these clinical results could be significant for the company’s growth trajectory.
Professor Stefano Spiezia, Chief of Endocrine Surgery at Ospedale del Mare who led the study, used the company’s CellFX nsPFA Percutaneous Electrode System under ultrasound guidance to ablate benign thyroid nodules.
"The results of this study are extremely compelling and demonstrate nsPFA’s ability to offer advantages in treating benign thyroid nodules compared to other methods such as thyroidectomy or thermal ablation," said Spiezia.
According to Dr. Ralph Tufano, Pulse Biosciences’ Scientific Advisory Board Chair, the nonthermal mechanism of nsPFA preserves surrounding nerves and blood vessels, allowing for treatment of nodules located near sensitive areas. He noted that nsPFA achieved a 71% reduction in nodule volume within one month, whereas radiofrequency ablation typically requires six months to reach comparable results.
The study showed no intranodular fibrosis or scarring on follow-up ultrasounds. A late-breaking abstract of this work was presented at the 2024 American Thyroid Association meeting.
The information in this article is based on a press release statement from Pulse Biosciences. For deeper insights into PLSE’s financial health, growth prospects, and 8 additional exclusive ProTips, visit InvestingPro, where you’ll find comprehensive analysis and the detailed Pro Research Report available for over 1,400 US stocks.
In other recent news, Pulse Biosciences reported its earnings for the second quarter of 2025, highlighting a notable increase in costs and expenses on both GAAP and non-GAAP bases. The company’s net loss expanded compared to the previous year, though its cash reserves stayed strong. Despite these financial hurdles, there was a slight rise in the stock during aftermarket trading. These developments are the latest updates concerning Pulse Biosciences’ financial situation. Analysts and investors will be keen to observe how the company manages its expenses and cash reserves moving forward. The earnings report provides essential insights into the company’s current financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.